 "Dr Reddy's launches Famotidine generic product in US to treat acidity")
Dr Reddy's Laboratories on Tuesday said it has launched over-the-counter (OTC) drug Famotidine tablets, used to treat gastroesophageal reflux disease, in the American market.
The company has launched the product, which is equivalent to Johnson & Johnson's Pepcid AC, in the US after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.
Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.
This launch will help us fulfil an important therapy gap created in antacids market due to Ranitidine withdrawal," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.
The Pepcid AC brand and generic versions had US sales of around USD 211 million for the 12 months ended in August 2020.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app